Recent 8-K filings for ANTX

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 11, 2026 20:06 UTC earnings item 2.02item 9.01

  AN2 Therapeutics Q1 net loss $10.0M; progresses oral epetraborole to Phase 2 for PV

source · ANTX on sec.gov